Why Voyager Therapeutics (VYGR) Shares Are Surging Today - Voyager Therapeutics (NASDAQ:VYGR), Neurocrine Biosciences (NASDAQ:NBIX)

Neurocrine Biosciences Inc NBIX and Voyager Therapeutics Inc VYGR have formed a new strategic collaboration to advance multiple gene therapies for neurological diseases.
Voyager will receive up-front consideration of $175 million, including a $39 million equity investment, up to $1.5 billion in potential development milestones, additional potential commercial milestones, tiered royalties on net sales, program funding, and an option to elect 50/50 cost- and profit-sharing in the U.S. for the GBA1 program following Phase 1 readout.
The collaboration includes Voyager's preclinical GBA1 gene therapy program for Parkinson's disease and other GBA1-mediated diseases, which combines a GBA1 gene replacement payload with novel capsids from Voyager's TRACER platform.
In addition, Neurocrine Biosciences and Voyager have also agreed to collaborate on three new gene therapy programs directed to rare CNS targets, each leveraging Voyager's novel TRACER capsids.
Regarding the GBA1 gene therapy program, Neurocrine Biosciences has agreed to fund development through the completion of a first Phase 1 trial.
Following the data readout, Voyager has the right, but not the obligation, to elect to co-develop and co-commercialize the GBA1 program with Neurocrine Biosciences in the U.S. under a 50/50 cost- and profit-sharing arrangement.
If Voyager declines its option for cost and profit sharing on the GBA1 program, it will be eligible for up to $985 million in total development milestone payments plus substantial potential commercial milestone payments and tiered royalties.
Price Action: VYGR shares are up 28.16% at $8.92 during the premarket session on the last check Monday.

Market News and Data brought to you by Benzinga APIs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Neurocrine Biosciences, Voyager Therapeutics Collaborate For Neurological-Focused Gene Therapies

Comments